HR Execs on the Move

Sudmo North America

www.sudmona.com

 
Sudmo North America is a Machesney Park, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.sudmona.com
  • 1330 Anvil Rd
    Machesney Park, IL USA 61115
  • Phone: 815.639.0322

Executives

Name Title Contact Details

Similar Companies

Agrios Global Holdings

Agrios Global Holdings Ltd. operates as a holding company. The Company, through its subsidiaries, provides aeroponic equipment rental, nutrient procurement, monitoring, and agronomy consultancy services. Agrios Global Holdings serves customers in Canada.

WCG IRB

WCG is the world`s leading provider of solutions that measurably improve the quality and efficiency of clinical research. Comprised of two divisions, the industry`s first central IRB – WCG IRB – and first clinical services organization, WCG enables biopharmaceutical companies, CROs, and institutions to advance the delivery of new treatments and therapies to patients, while maintaining the highest standards of human participant protection.

Integrated Nano-Technologies

Integrated Nano-Technologies is a Henrietta, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Harpoon Therapeutics

Harpoon Therapeutics is a clinical-stage immuno-oncology company developing a novel class of T cell engagers that harness the power of the body`s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient`s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon has also developed a proprietary ProTriTAC™ platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. Harpoon`s third proprietary technology platform, extended release TriTAC-XR, is designed to mitigate cytokine release syndrome.

Shenzhen Hepalink Pharmaceutical Co.

Hepalink was established in 1998 and restructured in 2007 to be a limited liability company.